(NVST) Envista Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29415F1049

Dental Implants, Orthodontic Products, Imaging Systems, Consumables, Software

Health Care Equipment
Market Cap in USD: 3,925m

IPO / Inception: 2019-09-18
Return 12m vs S&P 500: 3.02%

EPS (Earnings per Share)

EPS CAGR: -9.22%
EPS Trend: -69.5%

Last SUE: 0.54
Qual. Beats: 0

Revenue

Rev. CAGR: 0.73%
Rev. Trend: 9.2%

Last SUE: 1.59
Qual. Beats: 3

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	35.8%
Value at Risk 5%th	54.6%
Relative Tail Risk	-7.20%

Reward TTM
Sharpe Ratio	0.62
Alpha	-2.36
CAGR/Max DD	-0.20

Character TTM
Hurst Exponent	0.209
Beta	1.283
Beta Downside	1.180

Drawdowns 3y
Max DD	65.27%
Mean DD	44.00%
Median DD	50.95%

Description: NVST Envista Holdings January 10, 2026

Envista Holdings Corp (NVST) is a U.S.-based dental-technology company that sells a broad portfolio of products across two segments: Specialty Products & Technologies (dental implants, guided-surgery systems, orthodontic appliances, and related software) and Equipment & Consumables (digital imaging, endodontic and restorative supplies, and infection-prevention tools). Its brands include Nobel Biocare, Ormco, Dexis, DTX Studio and several others, serving oral surgeons, prosthodontists, periodontists, orthodontists and general dentists in the U.S., China and other international markets.

In 2023 Envista generated roughly $1.1 billion in revenue, with the Specialty Products segment contributing about 55 % and showing a 7 % year-over-year growth driven by rising demand for digital implant planning and clear-aligner therapy. The global dental implant market is projected to expand at a 6 % CAGR through 2028, while the broader digital dentistry segment is expected to outpace the overall healthcare equipment market, reflecting aging demographics and increasing consumer spending on cosmetic dentistry. Envista’s recent cost-control initiatives have lifted its adjusted EBITDA margin to ~12 %, and its 2024 guidance anticipates double-digit top-line growth, supported by expanding sales of its DTX Studio software suite.

For a deeper, data-driven look at NVST’s valuation metrics and peer comparison, you might find the analytics on ValueRay worth a quick glance.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (15.3m TTM) > 0 and > 6% of Revenue (6% = 157.3m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA -0.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 42.97% (prev 37.21%; Δ 5.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 300.1m > Net Income 15.3m (YES >=105%, WARN >=100%)

Net Debt (468.2m) to EBITDA (341.9m) ratio: 1.37 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.3m) change vs 12m ago -1.50% (target <= -2.0% for YES)

Gross Margin 55.37% (prev 53.69%; Δ 1.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 47.01% (prev 45.43%; Δ 1.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.09 (EBITDA TTM 341.9m / Interest Expense TTM 70.8m) >= 6 (WARN >= 3)

Altman Z'' 1.06

(A) 0.20 = (Total Current Assets 1.95b - Total Current Liabilities 821.7m) / Total Assets 5.64b

(B) -0.08 = Retained Earnings (Balance) -473.3m / Total Assets 5.64b

(D) -0.23 = Book Value of Equity -584.6m / Total Liabilities 2.55b

Total Rating: 1.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 52.64

1. Piotroski 5.50pt

2. FCF Yield 5.97%

3. FCF Margin 10.01%

4. Debt/Equity 0.52

5. Debt/Ebitda 1.37

6. ROIC - WACC (= -3.33)%

7. RoE 0.50%

8. Rev. Trend 9.21%

9. EPS Trend -69.51%

What is the price of NVST shares?

As of January 12, 2026, the stock is trading at USD 23.63 with a total of 2,193,564 shares traded.
Over the past week, the price has changed by +4.79%, over one month by +6.73%, over three months by +22.94% and over the past year by +24.43%.

Is NVST a buy, sell or hold?

Envista Holdings has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold NVST.

Strong Buy: 3
Buy: 0
Hold: 10
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the NVST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22.4	-5.3%
Analysts Target Price	22.4	-5.3%
ValueRay Target Price	24.2	2.2%

NVST Fundamental Data Overview January 10, 2026

P/E Trailing = 262.4445
P/E Forward = 19.1939
P/S = 1.4971
P/B = 1.2576
Beta = 0.995
Revenue TTM = 2.62b USD
EBIT TTM = 218.6m USD
EBITDA TTM = 341.9m USD
Long Term Debt = 1.45b USD (from longTermDebt, last quarter)
Short Term Debt = 39.2m USD (from shortTermDebt, last quarter)
Debt = 1.60b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 468.2m USD (from netDebt column, last quarter)
Enterprise Value = 4.39b USD (3.93b + Debt 1.60b - CCE 1.13b)
Interest Coverage Ratio = 3.09 (Ebit TTM 218.6m / Interest Expense TTM 70.8m)
EV/FCF = 16.74x (Enterprise Value 4.39b / FCF TTM 262.5m)
FCF Yield = 5.97% (FCF TTM 262.5m / Enterprise Value 4.39b)
FCF Margin = 10.01% (FCF TTM 262.5m / Revenue TTM 2.62b)
Net Margin = 0.58% (Net Income TTM 15.3m / Revenue TTM 2.62b)
Gross Margin = 55.37% ((Revenue TTM 2.62b - Cost of Revenue TTM 1.17b) / Revenue TTM)
Gross Margin QoQ = 55.26% (prev 54.27%)
Tobins Q-Ratio = 0.78 (Enterprise Value 4.39b / Total Assets 5.64b)
Interest Expense / Debt = 2.72% (Interest Expense 43.6m / Debt 1.60b)
Taxrate = -3.13% (negative due to tax credits) (33.9m / -1.08b)
NOPAT = 225.4m (EBIT 218.6m * (1 - -3.13%)) [negative tax rate / tax credits]
Current Ratio = 2.37 (Total Current Assets 1.95b / Total Current Liabilities 821.7m)
Debt / Equity = 0.52 (Debt 1.60b / totalStockholderEquity, last quarter 3.09b)
Debt / EBITDA = 1.37 (Net Debt 468.2m / EBITDA 341.9m)
Debt / FCF = 1.78 (Net Debt 468.2m / FCF TTM 262.5m)
Total Stockholder Equity = 3.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.27% (Net Income 15.3m / Total Assets 5.64b)
RoE = 0.50% (Net Income TTM 15.3m / Total Stockholder Equity 3.05b)
RoCE = 4.86% (EBIT 218.6m / Capital Employed (Equity 3.05b + L.T.Debt 1.45b))
RoIC = 5.04% (NOPAT 225.4m / Invested Capital 4.47b)
WACC = 8.37% (E(3.93b)/V(5.53b) * Re(10.64%) + D(1.60b)/V(5.53b) * Rd(2.72%) * (1-Tc(-0.03)))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.41%
[DCF Debug] Terminal Value 78.42% ; FCFF base≈266.6m ; Y1≈298.9m ; Y5≈397.9m
Fair Price DCF = 36.00 (EV 6.39b - Net Debt 468.2m = Equity 5.92b / Shares 164.4m; r=8.37% [WACC]; 5y FCF grow 14.07% → 2.90% )
EPS Correlation: -69.51 | EPS CAGR: -9.22% | SUE: 0.54 | # QB: 0
Revenue Correlation: 9.21 | Revenue CAGR: 0.73% | SUE: 1.59 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.28 | Chg30d=+0.004 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=1.27 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=+11.6% | Growth Revenue=+3.6%

Additional Sources for NVST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle